FinTechsDepot FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

  • HOME
  • ARTICLES
    • Digital banking
  • RESOURCES
    • Whitepaper
    • Infographics
  • GLOBENEWSWIRE NEWS
  • EVENTS
    • Upcoming conference
    • Past Conference
    • Webinar
  • Contact Us
FinTechsDepot
  • Home
  • Admin
  • Page 15

Author

Admin 425 posts 0 comments

Articles

How Digital Payments Are Reshaping the Future of Financial Trust

Admin Dec 2, 2025
Fintech is no longer a supporting industry — it has become the backbone of global commerce. Cashless payments,…
Featured News

New Salary-Law Rules Change Employee Financial Statements in India

Admin Dec 1, 2025
With the implementation of the Four Labour Codes from 21 November 2025, the way employees’ salaries are…
Articles

The Rise of Sustainable Finance: Why ESG Is Shaping the Future of Global…

Admin Nov 28, 2025
Finance is witnessing a paradigm shift as investors, regulators, and consumers increasingly prioritize…
Whitepaper

Turn Risk into Results: Unlocking Value in Your Fleet Claims & Safety

Admin Nov 27, 2025
Fleet incidents are more than just operational headaches; they're overlooked value leaks. This paper reveals how a…
Featured News

The Growing Adoption of Digital Payments and the Cashless Economy Revolution

Admin Nov 26, 2025
The financial sector is undergoing a transformative shift as consumers and businesses increasingly prefer digital…
Featured News

India’s Premium Housing Market Drives Value Despite Slower Volume

Admin Nov 25, 2025
India’s real estate landscape is witnessing a notable shift in 2025: even though the total number of homes sold is…
Featured News

Fintech-Driven Real Estate Platforms Gain Momentum as Digital Financing Transforms…

Admin Nov 24, 2025
A new market intelligence report released this week shows a dramatic rise in fintech-powered real estate…
Whitepaper

Driven by dollars: The role of compensation in life insurance agent placement…

Admin Nov 21, 2025
Compensation drives placement decisions in ways most don’t recognize. Case in point: 62% of agents actively prefer…
Featured News

Finance and Banking Fraud: The Silent Threat Undermining Global Trust

Admin Nov 20, 2025
Financial institutions worldwide are facing a wave of sophisticated fraud schemes driven by digital acceleration,…
Featured News

What’s Real and What’s Hype in 2026 Insurance

Admin Nov 19, 2025
Go beyond the buzzwords. This report cuts through the hype to reveal the real shifts in AI, climate risk, embedded…
Older Posts
Newer Posts

    SUBSCRIBE NOW


    Via Email
    Via Telephone


    I Agree. I would like to share my information with FinTechsDepot & their partners so that I can receive relevant information about products, services, & offers.

    RECENT POST

    • FinTech and Employee F&F Settlement: How Digital Financial Platforms Are Transforming the Employee Exit Process
    • How AI and Digital Innovation Are Transforming the Future of the FinTech Industry
    • The Power of Ecosystems for Banking
    • The Rise of Fintech: Transforming the Financial Landscape
    • Why Financial Services and Banks Need an Operational Data Layer

    ARTICLE

    Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
    2026-08-13T01:45:00Z
    ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for...


    Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
    2026-08-13T01:45:00Z
    SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative...


    NOTICE TO DISREGARD -- Leading Edge Health Inc
    2026-08-12T22:00:35Z
    LAS VEGAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- We are advised by VITALIBOOST LLC that journalists and other readers should disregard the news release, “Load Boost: Semenax, Volume Pills or...


    NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
    2026-08-12T21:02:00Z
    The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial Production


    Park Dental Partners Announces Second Quarter 2026 Results
    2026-08-12T20:33:00Z
    MINNEAPOLIS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its second...


    Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    2026-08-12T20:29:33Z
    - U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -


    AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    2026-08-12T20:15:00Z
    - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program


    First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-12T20:15:00Z
    SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory...


    BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
    2026-08-12T20:15:00Z
    KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire...


    Range Impact Reports 2Q 2026 Financial Results
    2026-08-12T20:10:00Z
    CLEVELAND, OHIO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming, and redeveloping legacy coal mines...


    Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
    2026-08-12T20:05:00Z
    Company announcement – No. 38 / 2026


    Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
    2026-08-12T20:05:00Z
    SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for...


    Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
    2026-08-12T20:05:00Z
    MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial...


    SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
    2026-08-12T20:05:00Z
    Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025


    Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-12T20:05:00Z
    – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD –


    Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
    2026-08-12T20:05:00Z
    Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV


    Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
    2026-08-12T20:05:00Z
    SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver...


    MaxCyte Reports Second Quarter 2026 Financial Results
    2026-08-12T20:05:00Z
    ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation...


    Lumexa Imaging Announces Second Quarter 2026 Results
    2026-08-12T20:05:00Z
    RALEIGH, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended...


    RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
    2026-08-12T20:05:00Z
    Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M


    BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
    2026-08-12T20:05:00Z
    SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial...


    BioStem Technologies Reports Second Quarter 2026 Financial Results
    2026-08-12T20:05:00Z
    Generates 29% sequential revenue growth, increasing to $7.9 million;Raises full-year 2026 revenue guidanceUplists to Nasdaq Capital Market


    Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
    2026-08-12T20:05:00Z
    WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial...


    Kura Oncology Reports Second Quarter 2026 Financial Results
    2026-08-12T20:02:00Z
    – KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –


    Acquisition of Own Shares
    2026-08-12T20:01:00Z
    Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information


    ArriVent BioPharma Reports Second Quarter 2026 Financial Results
    2026-08-12T20:01:00Z
    NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...


    Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
    2026-08-12T20:01:00Z
    CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results...


    Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
    2026-08-12T20:01:00Z
    Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter


    Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
    2026-08-12T20:01:00Z
    ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for...


    Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
    2026-08-12T20:01:00Z
    PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

    Copyright © 2026 | FinTechsDepot | All Rights Reserved |
    Privacy Policy | Unsubscribe
    Sign in

    Welcome, Login to your account.

    Forget password?
    Sign in

    Recover your password.

    A password will be e-mailed to you.